[ad_1] New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1 Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function – vs. patients’ historic […]
Tag: Clinical Trials & Medical Discoveries
RiboX Therapeutics Announces FDA Clearance for IND Application of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
[ad_1] PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ — RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, announced that the US Food and Drug Administration (FDA) has […]
Independent meta-analyses by Melanoma Institute of Australia on CP-GEP model in Melanoma Care
[ad_1] ROTTERDAM, Netherlands and SAN DIEGO, Oct. 24, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announced today the results […]
Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
[ad_1] STOCKHOLM, Oct. 24, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the Clinical Trials for […]
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
[ad_1] Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and indicated by the FDA1 Recommendation comes after recent FDA […]
